Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Rytelewski, Mateusz ^a   Meilleur, Courtney E ^a   Yekta, Maryam Atef ^a   Szabo, Peter A ^a   Garg, Nitan ^a   Schell, Todd D ^b   Jevnikar, Anthony M ^a   Sharif, Shayan ^c   Singh, Bhagirath ^a   Haeryfar, S M Mansour ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL DEXTRO TRYPTOPHAN; CD4 ANTIGEN; EPITOPE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; IMMUNITY; IMMUNODOMINANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFLUENZA VIRUS A; INTERFERON PRODUCTION; KIDNEY TUMOR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SIMIAN VIRUS 40; VIRAL CLEARANCE; WILD TYPE;

ANIMALS; ANTIGENS, CD4; ANTIGENS, POLYOMAVIRUS TRANSFORMING; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; IMMUNE TOLERANCE; IMMUNITY, INNATE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLUENZA A VIRUS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KYNURENINE; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; T-LYMPHOCYTES, REGULATORY; TRYPTOPHAN;

EID: 84896522334     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090439     Document Type: Article

References (76)

1. Yewdell JW, Bennink JR (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17: 51-88. (Pubitemid 29241119)
2. Yewdell JW, Haeryfar SM (2005) Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Annu Rev Immunol 23: 651-682. (Pubitemid 40563182)
3. Liu Y, Linsley PS (1992) Costimulation of T-cell growth. Curr Opin Immunol 4: 265-270.
4. Sharpe AH (2009) Mechanisms of costimulation. Immunol Rev 229: 5-11.
5. Chen W, Masterman KA, Basta S, Haeryfar SM, Dimopoulos N, et al. (2004) Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon. Eur J Immunol 34: 194-199. (Pubitemid 38111535)
6. Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S (2006) Dendritic cells crossdressed with peptide MHC class I complexes prime CD8+ T cells. J Immunol 177: 6018-6024. (Pubitemid 44628815)
7. Wakim LM, Bevan MJ (2011) Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection. Nature 471: 629-632.
8. Haeryfar SM, DiPaolo RJ, Tscharke DC, Bennink JR, Yewdell JW (2005) Regulatory T cells suppress CD8+ T cell responses induced by direct priming and cross-priming and moderate immunodominance disparities. J Immunol 174: 3344-3351. (Pubitemid 40354038)
9. Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4: 762-774. (Pubitemid 39336293)
10. Orabona C, Grohmann U (2011) Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond. Methods Mol Biol 677: 269-280.
11. Munn DH, Sharma MD, Mellor AL (2004) Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 172: 4100-4110. (Pubitemid 38375222)
12. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, et al. (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196: 459-468.
13. Molano A, Illarionov PA, Besra GS, Putterman C, Porcelli SA (2008) Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase. Immunol Lett 117: 81-90.
14. Liu H, Liu L, Liu K, Bizargity P, Hancock WW, et al. (2009) Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenasedependent immune suppression. J Immunol 183: 1022-1031.
15. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9: 1269-1274. (Pubitemid 37279849)
16. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, et al. (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 117: 2570-2582. (Pubitemid 47494358)
17. Zhang G, Liu WL, Zhang L, Wang JY, Kuang MH, et al. (2011) Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma. Clin Dev Immunol 2011: 384726.
18. Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, et al. (2009) Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 115: 185-192.
19. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, et al. (2008) Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 14: 2310-2317. (Pubitemid 351551062)
20. Becerra A, Warke RV, Xhaja K, Evans B, Evans J, et al. (2009) Increased activity of indoleamine 2,3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function. J Gen Virol 90: 810-817.
21. Mao R, Zhang J, Jiang D, Cai D, Levy JM, et al. (2011) Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol 85: 1048-1057.
22. Hoshi M, Saito K, Hara A, Taguchi A, Ohtaki H, et al. (2010) The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J Immunol 185: 3305-3312.
23. Yoshida R, Urade Y, Tokuda M, Hayaishi O (1979) Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. Proc Natl Acad Sci U S A 76: 4084-4086. (Pubitemid 9249028)
24. Huang L, Li L, Klonowski KD, Tompkins SM, Tripp RA, et al. (2013) Induction and role of indoleamine 2,3 dioxygenase in mouse models of influenza a virus infection. PLoS One 8: e66546.
25. Trinchieri G, Aden DP, Knowles BB (1976) Cell-mediated cytotoxicity to SV40-specific tumour-associated antigens. Nature 261: 312-314.
26. Knowles BB, Koncar M, Pfizenmaier K, Solter D, Aden DP, et al. (1979) Genetic control of the cytotoxic T cell response to SV40 tumor-associated specific antigen. J Immunol 122: 1798-1806. (Pubitemid 9180032)
27. Shen Z, Reznikoff G, Dranoff G, Rock KL (1997) Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158: 2723-2730. (Pubitemid 127470530)
28. Leon-Ponte M, Kasprzyski T, Mannik LA, Haeryfar SM (2008) Altered immunodominance hierarchies of influenza A virus-specific H-2(b)-restricted CD8+ T cells in the absence of terminal deoxynucleotidyl transferase. Immunol Invest 37: 714-725.
29. Crowe SR, Miller SC, Woodland DL (2006) Identification of protective and non-protective T cell epitopes in influenza. Vaccine 24: 452-456. (Pubitemid 41832548)
30. Belz GT, Xie W, Altman JD, Doherty PC (2000) A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge. J Virol 74: 3486-3493. (Pubitemid 30180290)
31. Mylin LM, Schell TD, Roberts D, Epler M, Boesteanu A, et al. (2000) Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes. J Virol 74: 6922-6934. (Pubitemid 30470675)
32. Munn DH (2012) Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed) 4: 734-745.
33. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, et al. (2002) Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 107: 452-460. (Pubitemid 36693650)
34. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, et al. (2006) The combined effects of tryptophan starvation and tryptophan catabolites downregulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176: 6752-6761. (Pubitemid 43787857)
35. Livingston DM, Bradley MK (1987) The simian virus 40 large T antigen. A lot packed into a little. Mol Biol Med 4: 63-80.
36. Fu TM, Mylin LM, Schell TD, Bacik I, Russ G, et al. (1998) An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol 72: 1469-1481. (Pubitemid 28116935)
37. Watson AM, Mylin LM, Thompson MM, Schell TD (2012) Modification of a Tumor Antigen Determinant To Improve Peptide/MHC Stability Is Associated with Increased Immunogenicity and Cross-Priming a Larger Fraction of CD8+ T Cells. J Immunol 189: 5549-5560.
38. Maleki VS, Harding MJ, Waithman J, Zanker D, Shivji AN, et al. (2012) Differential regulation of simultaneous antitumor and alloreactive CD8(+) T-cell responses in the same host by rapamycin. Am J Transplant 12: 233-239.
39. Cady SG, Sono M (1991) 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)- DLalanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]- DLalanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 291: 326-333.
40. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11: 312-319. (Pubitemid 40460560)
41. Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147-1154. (Pubitemid 46718399)
42. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, et al. (2007) Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67: 792-801. (Pubitemid 46192220)
43. Okamoto H, Itoh K, Welsh E, Trial J, Platsoucas C, et al. (1988) In vitro cytotoxic activity of interleukin 2-dependent murine Thy-1+ dendritic epidermal cell lines. J Leukoc Biol 43: 502-508.
44. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, et al. (2002) T cell apoptosis by tryptophan catabolism. Cell Death Differ 9: 1069-1077.
45. Della CM, Carlomagno S, Frumento G, Balsamo M, Cantoni C, et al. (2006) The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK-cell function. Blood 108: 4118-4125. (Pubitemid 44913283)
46. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, et al. (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189: 1363-1372. (Pubitemid 29227522)
47. Falk K, Rotzschke O, Deres K, Metzger J, Jung G, et al. (1991) Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J Exp Med 174: 425-434.
48. Vitiello A, Yuan L, Chesnut RW, Sidney J, Southwood S, et al. (1996) Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J Immunol 157: 5555-5562. (Pubitemid 126448977)
49. Belz GT, Xie W, Doherty PC (2001) Diversity of epitope and cytokine profiles for primary and secondary influenza a virus-specific CD8+ T cell responses. J Immunol 166: 4627-4633. (Pubitemid 32233749)
50. Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, et al. (2001) A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 7: 1306-1312. (Pubitemid 34007934)
51. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, et al. (1986) The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44: 959-968. (Pubitemid 16045342)
52. Chen W, Pang K, Masterman KA, Kennedy G, Basta S, et al. (2004) Reversal in the immunodominance hierarchy in secondary CD8+ T cell responses to influenza A virus: roles for cross-presentation and lysis-independent immunodomination. J Immunol 173: 5021-5027. (Pubitemid 39387784)
53. Kassem A, Schopflin A, Diaz C, Weyers W, Stickeler E, et al. (2008) Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res 68: 5009-5013.
54. Houben R, Shuda M, Weinkam R, Schrama D, Feng H, et al. (2010) Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 84: 7064-7072.
55. Spurgeon ME, Lambert PF (2013) Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. Virology 435: 118-130.
56. Sihto H, Bohling T, Kavola H, Koljonen V, Salmi M, et al. (2012) Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a populationbased study. Clin Cancer Res 18: 2872-2881.
57. Gomez BP, Wang C, Viscidi RP, Peng S, He L, et al. (2012) Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen. Cell Biosci 2:
58. Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, et al. (2011) Merkel cell polyomavirus-specific CD8(+) and CD4(+) T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res 17: 6671-6680.
59. Fox JM, Sage LK, Huang L, Barber J, Klonowski KD, et al. (2013) Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection. J Gen Virol 94: 1451-1461.
60. Irvine K, Bennink J (2006) Factors influencing immunodominance hierarchies in TCD8+-mediated antiviral responses. Expert Rev Clin Immunol 2: 135-147. (Pubitemid 44355602)
61. Tatum AM, Mylin LM, Bender SJ, Fischer MA, Vigliotti BA, et al. (2008) CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors. J Immunol 181: 4406-4417.
62. Schell TD, Tevethia SS (2001) Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen. J Immunol 167: 6947-6956. (Pubitemid 33144189)
63. Rimmelzwaan GF, Boon AC, Voeten JT, Berkhoff EG, Fouchier RA, et al. (2004) Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Virus Res 103: 97-100. (Pubitemid 38649067)
64. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, et al. (1991) Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354: 453-459. (Pubitemid 21896855)
65. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH (2002) Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 168: 3771-3776. (Pubitemid 34298376)
66. Liu Z, Dai H, Wan N, Wang T, Bertera S, et al. (2007) Suppression of memory CD8 T cell generation and function by tryptophan catabolism. J Immunol 178: 4260-4266. (Pubitemid 46492376)
67. Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, et al. (2009) Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumordraining lymph nodes. Blood 113: 6102-6111.
68. Sharma MD, Hou DY, Baban B, Koni PA, He Y, et al. (2010) Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 33: 942-954.
69. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, et al. (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633. (Pubitemid 43121851)
70. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, et al. (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112: 610-618.
71. Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, et al. (2011) The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS One 6: e19823.
72. Weber WP, Feder-Mengus C, Chiarugi A, Rosenthal R, Reschner A, et al. (2006) Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol 36: 296-304. (Pubitemid 43257452)
73. Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, et al. (2010) Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 84: 304-309.
74. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, et al. (2005) GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22: 633-642. (Pubitemid 40719198)
75. Taylor MW, Feng GS (1991) Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5: 2516-2522. (Pubitemid 21905800)
76. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, et al. (2002) CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3: 1097-1101. (Pubitemid 35363664)